Article Text

other Versions

PDF
Randomised trial of once- or twice-daily MMX™ mesalazine for maintenance of remission in ulcerative colitis
  1. Michael A Kamm (kamm{at}ic.ac.uk)
  1. St Vincent's Hospital, Australia
    1. Gary R Lichtenstein
    1. University of Pennsylvania, United States
      1. William J Sandborn
      1. Mayo Clinic, United States
        1. Stefan Schreiber
        1. Christian-Albrechts-Universität, Germany
          1. Kirstin H Lees
          1. Shire Pharmaceuticals Inc., United States
            1. Karen Barrett
            1. Shire Pharmaceuticals Inc., United Kingdom
              1. Raymond E Joseph
              1. Shire Pharmaceuticals Inc., United States

                Abstract

                Aim: Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once daily, high-strength (1.2 g/tablet) formulation of 5 aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis.

                Methods: This multicentre, randomised, open-label trial enrolled patients with strictly defined clinical and endoscopic remission, immediately following an episode of mild-to-moderate ulcerative colitis. Patients were randomised to MMX mesalazine 2.4 g/day as a single (2 x 1.2 g tablet) or divided dose (1 x 1.2 g tablet twice daily) for 12 months.

                Results: 174 patients (37.9%; safety population n=459) experienced 384 adverse events, the majority of which were mild or moderate in intensity. Eighteen patients (3.9%), 9 in each group, experienced a total of 22 serious adverse events (10 in the once-daily and 12 in the twice-daily group). Most serious adverse events were gastrointestinal, experienced by 5 patients in the once-daily and 4 in the twice-daily group. At month 12, 64.4% (efficacy population, n=451) of patients in the once-daily and 68.5% of patients in the twice-daily group were in clinical and endoscopic remission (p=0.351). At month 12, 88.9% and 93.2% in each group, respectively, had maintained clinical remission (were 'relapse-free').

                Conclusions: MMX mesalazine 2.4 g/day administered as a single or divided dose demonstrated a good safety profile, was well tolerated and was effective as maintenance treatment. High clinical and endoscopic remission rates can be achieved with once-daily dosing.

                • Inflammatory bowel disease
                • MMX mesalazine
                • Ulcerative colitis

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                Linked Articles

                • Digest
                  Robin Spiller Magnus Simren